Skip to content

A prospective, single-arm clinical study to evaluate the safety and efficacy of superior vena cava isolation combined with modified posterior wall plus autonomic ganglion ablation in the treatment of persistent atrial fibrillation

A prospective, single-arm clinical study to evaluate the safety and efficacy of superior vena cava isolation combined with modified posterior wall plus autonomic ganglion ablation in the treatment of persistent atrial fibrillation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092589
Enrollment
Unknown
Registered
2024-11-19
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

PVI + Modified PWI + SVC + GPgroup:Superior vena cava isolation combined with improved wall and autonomous ganglion ablation

Sponsors

Mianyang 404 Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Age range: 18-80 years old; 2) First non valvular AF catheter ablation; 3) Persistent AF lasting for more than 7 days but less than 3 years, including termination of episodes through cardioversion (medication or electrical cardioversion) after>7 days; 4) The patient has AF related symptoms, including but not limited to palpitations, pre syncope/syncope, fatigue, and shortness of breath; 5) The use of one or more antiarrhythmic drugs (AAD) is ineffective; 6) Agree to undergo radiofrequency ablation treatment and be able to receive follow-up as required

Exclusion criteria

Exclusion criteria: 1) Unable to complete the expected 1-year follow-up; 2) Serious hematological disorders with contraindications to anticoagulation; 3) Left room diameter >= 55mm; 4) Other arrhythmias/malignant arrhythmias; 5) NYHA functional class IV; 6) Hyperthyroidism or hypothyroidism; 7) Patients with severe renal insufficiency (eGFR<30ml/min/1.73m2) or those who have received dialysis or renal replacement therapy in the past The person; 8) Expected lifespan<1 year; 9) Those with surgical contraindications;

Design outcomes

Primary

MeasureTime frame
The recurrence rate after atrial fibrillation surgery;Safety of surgery;

Secondary

MeasureTime frame
Quality of life evaluation;

Countries

China

Contacts

Public ContactZhou Tao

Mianyang 404 Hospital

331762177@qq.com+86 135 6853 0770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026